financetom
Business
financetom
/
Business
/
BioMarin Pharmaceutical to Acquire Inozyme Pharma for $270 Million
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
BioMarin Pharmaceutical to Acquire Inozyme Pharma for $270 Million
May 26, 2025 9:26 AM

07:55 AM EDT, 05/16/2025 (MT Newswires) -- BioMarin Pharmaceutical ( BMRN ) said Friday that it has agreed to acquire Inozyme Pharma ( INZY ) at $4 per share in cash for a total price of $270 million.

The biotech company said the deal is expected to close in Q3, which is contingent on regulatory approval, completion of a tender offer, and other customary closing conditions.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Preview: Phaos Technology Holdings  Limited Set To IPO Tomorrow
Preview: Phaos Technology Holdings Limited Set To IPO Tomorrow
Nov 12, 2025
Phaos Technology Holdings Limited ( POAS ) IPO will take place November, 13 on the NYSE exchange under the ticker POAS. The company is offering shares at an expected price between $4.00 and $5.00 per share with an insider lock-up period of 180 days ending on May 12, 2026. See also: Benzinga IPO Calendar About Phaos Technology Holdings Limited Phaos...
Form 8.3
Form 8.3
Nov 12, 2025
LONDON--(BUSINESS WIRE)--   FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Verition Fund Management LLC (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee...
Form 8.3
Form 8.3
Nov 12, 2025
LONDON--(BUSINESS WIRE)--   FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Verition Fund Management LLC (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee...
Form 8.3
Form 8.3
Nov 12, 2025
LONDON--(BUSINESS WIRE)--   FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Verition Fund Management LLC (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee...
Copyright 2023-2026 - www.financetom.com All Rights Reserved